7/28/2011

Affymax and Takeda Pharmaceutical's drug candidate peginesitide was accepted for FDA review. Formerly named Hematide, the once-monthly drug is intended for anemia in kidney patients on dialysis.

Full Story:
Xconomy

Related Summaries